SPOTLIGHT -
Immunotherapy's Promise Extends to Bladder and Renal Cell Cancer
News stories coming out of the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC) were focused on the emerging role of immunotherapy and radiotherapy in bladder, renal, and prostate cancer.
Men With High-Risk Prostate Cancer Undergoing More Prostatectomies
Recent trends suggest a shift away from radiation therapy and more toward radical prostatectomy for patients with high-risk prostate cancer.
Personalized Peptide Vaccination Increased Survival in Advanced Bladder Cancer
The prognosis for patients with bladder cancer who have progressed after platinum-based chemotherapy is poor, but the results of a phase II study involving an immunotherapy hold promise.
Swedish Biomarker Test STHLM3 Identifies Aggressive Form of Prostate Cancer
A test called the Stockholm 3 (STHLM3) has been shown to detect aggressive prostate cancer cancer earlier, reduce the number of false positives, and decrease the number of unnecessary biopsies.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
